The human epidermal growth factor 2 (HER-2) overexpressing subtype accounts for 15–20% of all breast cancer cases [2] and, along with triple-negative, is historically associated with more aggressive behavior and a worse overall prognosis [3,4]. This evidence concerns the gene ERBB2 and breast cancer.